You can rely on the Cardinal Health™ Flu Vaccine Program to help keep patients and staff healthy year-round. Experience peace of mind and be prepared for every flu season with access to competitive pricing and a broad product portfolio. ...
Influenza Vaccine Market Size, Share & Industry Analysis, By Type (Inactivated and Live Attenuated), By Valency (Quadrivalent and Trivalent), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast, 2024-2...
An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high...
PediatricAppropriate studies have not been performed on the relationship of age to the effects of Agriflu®, Flulaval™, Fluzone® High-Dose, Fluzone® Intradermal, or Fluzone® Intradermal Quadrivalent in the pediatric population. Safety and efficacy have not been established. ...
Although most inactivated influenza virus vaccines available in the US for use in adults and pediatric patients ≥6 month of age are egg-based vaccines (Afluria, Fluarix, Flulaval, Fluzone), a cell culture-based vaccine (Flucelvax) also is available for use in individuals ≥6 months of age....
The Influenza Vaccine Market is Segmented by Vaccine Type (Quadrivalent and Trivalent), Type (Seasonal and Pandemic), Technology (Egg-based and Cell-based), Age Group (Pediatric and Adults), Route of Administration (Injection and Nasal Spray), and Geography (North America, Europe, Asia-Pacific,...
2-dose series: 0.5 mL intramuscular (IM) administered 21 days apart Pediatric: Indicated for active immunization to prevent disease caused by the influenza A virus H5N1 subtype in patients aged above 6 months at increased risk of exposure
The potential for future development of these novel influenza vaccine candidates is discussed from an industry perspective.Background Seasonal influenza outbreaks cause 3 to 5 million cases of severe illness and 290,000 to 650,000 respiratory deaths each year [1, 2]. The Orthomyxoviridae are a ...
Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030) Inactivated Live Attenuated Indication Outlook (Revenue, USD Million, 2018 - 2030) Quadrivalent Trivalent Age Group Outlook (Revenue, USD Million, 2018 - 2030) Pediatric Adult Route of Administration Outlook (Revenue, USD Million, 2018 - ...
Influenza virus vaccine (Advanced Reading) Influenza virus vaccine, adjuvanted (Advanced Reading) Influenza Virus Vaccine (Inactivated) Other brands Fluzone, Afluria, Flucelvax Quadrivalent, Fluzone High-Dose, ... +18 more Professional resources Influenza Vaccine Recombinant monograph Influenza Virus Vaccine...